M JOEL ROTH

Rhumatologue

📍 PARIS (75)LibéralRPPS 10000395078

✨ Profil synthétique

IA · 19/05/2026

Le Dr M JOEL ROTH est un rhumatologue libéral exerçant à Paris. Ses publications sur PubMed révèlent une expertise dans le traitement de pathologies rhumatismales, notamment chez les patients pédiatriques. Ses travaux de recherche portent sur l'utilisation de csDMARDs et de biothérapies non-anti-TNF.

Expertises présumées

Arthrite juvénile
Pédiatrie
csDMARDs
Biothérapies non-anti-TNF
Corticothérapie
Spondyloarthrite

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Lieux de consultation(2)

CABINET DU DR JOEL ROTH
128 BOULEVARD MACDONALD, 75019 PARIS
Activité de soin et de pharmacie
CABINET DU DR JOEL ROTH
S O S MEDECINS 87 BOULEVARD DE PORT ROYAL, 75013 PARIS
Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Emergent high fatality lung disease in systemic juvenile arthritis

Annals of the rheumatic diseases · 2019

📚 168 citations🎯 RCR 8.54Top 3% NIH🔓 Open Access

Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study

Rheumatology (Oxford, England) · 2021

📚 56 citations🎯 RCR 4.98Top 8% NIH🩺 Clinique🔓 Open Access

Lire l'abstract Crossref ↓

Abstract Objectives Efficacy evaluation of GCA treatment is primarily based on non-specific symptoms and laboratory markers. We aimed to assess the change in vascular inflammation in patients with large vessel (LV)-GCA under different treatments using [18F]FDG PET/CT. Methods Observational study on patients with new-onset, active LV-GCA starting treatment with either prednisolone monotherapy (PRED) or combination with MTX or tocilizumab (TOC). All patients underwent baseline and follow-up PET/CT. The aorta and its major branches were assessed using PET vascular activity score (PETVAS) by independent readers. Cumulative glucocorticoid doses and cessation of glucocorticoid treatment were documented in all patients. Results We included 88 LV-GCA patients, 27 were treated with PRED, 42 with MTX and 19 with TOC. PETVAS decreased from 18.9–8.0 units at follow-up in the overall population (P &lt;0.001). PETVAS changes were numerically higher in patients receiving MTX (−12.3 units) or TOC (−11.7 units) compared with PRED (−8.7). Mean cumulative prednisolone dosages were 5637, 4418 and 2984 mg in patients treated with PRED, MTX and TOC (P =0.002). Risk ratios for glucocorticoid discontinuation at the time of follow-up PET/CT were 6.77 (95% CI: 1.01, 45.29; P =0.049) and 16.25 (95% CI: 2.60, 101.73; P =0.003) for MTX and TOC users compared with PRED users. Conclusion Treatment of LV-GCA inhibits vascular inflammation in the aorta and its major branches. While similar control of vascular inflammation was achieved with PRED, MTX and TOC treatments, TOC showed a strong glucocorticoid sparing effect, supporting the concept of initial combination therapy.

S100A8/A9-alarmin promotes local myeloid-derived suppressor cell activation restricting severe autoimmune arthritis

Cell reports · 2023

📚 30 citations🎯 RCR 3.30Top 14% NIH🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

M JOEL ROTH

Pourquoi vous devez consulter ce praticien

Lieux de consultation(2)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal27

Arthrite juvénile15

Pédiatrie7

csDMARDs2

Biothérapies non-anti-TNF1

Corticothérapie1

Spondyloarthrite1

Partager cette fiche